http://www.brca.com/legal-notice-and-terms-of-use.html
Skip to content
skip to navigation
Search
Menu
Search
Search
Search
Close
What science can do
R&D
R&D
Our approach
Transformative science
Data science & AI
Our technologies
Next generation therapeutics
Publications
R&D strategic centres
Our therapy areas
All therapy areas
Oncology
Cardiovascular, Renal and Metabolism
Respiratory & Immunology
Other disease areas
Pipeline
All medicines
Our company
Our company
Our strategy
Our people
Our commitment to patients
Leadership team
Cambridge
Gothenburg
Gaithersburg
Careers
Investors
Investor Relations (Global)
Investor Relations (Sweden)
Stock Exchange announcements
Results and presentations
Annual Reports
Governance
Shareholder information
Dividend policy
Key facts
FAQs
Debt Investors
ADR Programme
Media
Press Releases
Media centre
Articles
Image library
COVID-19 visual resources
Broadcast videos
Archive
Media contacts
Sustainability
Sustainability
Access to healthcare
Environmental protection
Ethics and transparency
Resources
Partnering
Partnering with AstraZeneca
Our Partnering teams
Our areas of partnering interest
Why partner with AstraZeneca?
Secrets to successful partnering
Supplier Information
More
Hide
AstraZeneca Websites
Global site
COVID-19 Information Hub
Read more
Article
Transforming the breast cancer patient experience requires a collective collaborative approach
Article
Gold standard recognition for global climate and water stewardship
The COVID-19 pandemic is a challenge to humanity that demands a global united response.
Learn how Per is working to ensure broad, equitable and timely access to our potential vaccine
Publications
Our innovative science means a strong track-record of publication in peer-reviewed journals, contributing to the foundation of scientific advancement.
View our publications
We have
172
projects in our pipeline
View pipeline
Explore our technology
Our Cambridge site (UK) is one of AstraZeneca's three global strategic science centres
Explore all our science centres
Creating the next generation of therapeutics
We are constantly pushing the boundaries of science to deliver life-changing medicines which will have the greatest and swiftest impact on the diseases we are aiming to treat, prevent, modify and in the future, even cure.
Find out more
Corporate Press Release
Enhertu continues to demonstrate durable responses with new data from DESTINY-Breast01 in HER2-positive metastatic breast cancer
10 December 2020
Corporate Press Release
AZD1222 Oxford Phase III trials interim analysis results published in The Lancet
8 December 2020
You are now leaving AstraZeneca.com
You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.
AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.
Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.
Cancel
Continue
?
Important notice for users
You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information.
I have read this warning and will not be using any of the contained product information for clinical purposes.
I disagree
I agree
?
?